HANZEMA DIN 02477432
Health Canada record
| Active ingredient(s) | ALITRETINOIN 10 MG |
|---|---|
| Dosage form | Capsule |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | D11AH04 ALITRETINOIN |
| Original market date | 09-Jun-2021 |
| Current status date | 09-Jun-2021 |
| Source | Health Canada DPD |
Establishment licence of the holder
Dr. Reddy's Laboratories Canada Inc — licence 102182, currently licensed, last inspection rating C (2025-05-06).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing ALITRETINOIN
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02477440 | HANZEMA | DR. REDDY'S LABORATORIES INC | Capsule | ALITRETINOIN 30 MG | Marketed |
| 02240328 | PANRETIN | LIGAND PHARMACEUTICALS INC | Gel | ALITRETINOIN 0.1 % | Cancelled (Unreturned Annual) |
| 02337630 | TOCTINO | GLAXOSMITHKLINE INC | Capsule | ALITRETINOIN 10 MG | Cancelled Post Market |
| 02337649 | TOCTINO | GLAXOSMITHKLINE INC | Capsule | ALITRETINOIN 30 MG | Cancelled Post Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 21230 | 2018-08-20 | Abbreviated New Drug Submission (ANDS) |
International API supply for ALITRETINOIN
2 active FDA Drug Master Files.
Request a quote for HANZEMA